Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY3143921 |
| Synonyms | |
| Therapy Description |
LY3143921 is an ATP-competitive CDC7 inhibitor that inhibits cell-cycle progression, which may lead to anti-tumor activity (J Clin Oncol 37, 2019 (suppl; abstr TPS3167)). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY3143921 | LY 3143921|LY-3143921 | CDC7 Inhibitor 4 | LY3143921 is an ATP-competitive CDC7 inhibitor that inhibits cell-cycle progression, which may lead to anti-tumor activity (J Clin Oncol 37, 2019 (suppl; abstr TPS3167)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |